Octane Medical acquires B. Braun’s world orthobiologics enterprise

Article content material

“From the beginning, our company mission has been to make regenerative drugs the usual of care. We proceed to be true to this objective, and it’s the important thing motive why we pursued this chance.”

— Octane Medical Group CEO Timothy Smith.

KINGSTON, Ontario and MELSUNGEN, Germany, June 07, 2024 (GLOBE NEWSWIRE) — Octane Medical Group, by means of its new enterprise Octane Biotherapeutics (BioTx), has acquired 100% shares of the worldwide orthobiologics enterprise from its long-term companion B. Braun. The acquisition, consisting of the 2 firms TETEC AG in Germany and Aesculap Biologics, LLC. in america, establishes Octane as a world chief in regenerative drugs. 

Article content material

The orthobiologics platform presently contains two merchandise: NOVOCART 3D, which implants a collagen-based matrix scaffold seeded with cartilage cells into the faulty space, and NOVOCART Inject, an injectable combination of cartilage cells and PEG-albumin-hyaluronic acid hydrogel. 

“Octane beforehand partnered with B. Braun for greater than 10 years to scale up manufacturing of living-tissue orthopedic implants,” stated Timothy Smith, CEO and co-founder of Octane, a worldwide chief in regenerative drugs with probably the most superior applied sciences in cell remedy, spinal implants, medical imaging and bioelectricity. “This acquisition brings the NOVOCART autologous chondrocyte implantation (ACI) expertise for articular cartilage restore into the innovation portfolio at Octane, giving the corporate full possession of the NOVOCART worth chain – from design growth, medical trials and manufacturing by means of to gross sales, distribution and medical use.”

Pivotally, the acquisition additionally permits Octane to leverage the automated cell manufacturing capabilities of its Cocoon bioreactor to broaden and speed up manufacturing of NOVOCART articular cartilage implants. This positions Octane to change into the primary ACI remedy supplier to considerably cut back manufacturing prices, whereas growing consistency, high quality, and scalability because of Cocoon’s automated manufacturing platform.

Article content material

Article content material

Cocoon, a first-of-its-kind automated manufacturing system for customized cell therapies, manufactures cells in a exactly managed bioreactor for functions in a various vary of important ailments and circumstances. Octane’s objective is to transition NOVOCART from its present guide manufacturing course of to full automation with Cocoon.

“The mixture of NOVOCART and Cocoon will result in improved high quality, larger capability and operational flexibility, plus increased product margins,” stated Ian Grant, COO and co-founder of Octane. “This may, in flip, additional allow environment friendly worldwide turnkey growth, notably into the European Union and North American markets.”

Dr. Jens von Lackum, a member of the B. Braun Board and chairman of the Government Board of Aesculap AG, acknowledged that the entire sale of the orthobiologics enterprise to Octane is a part of Aesculap’s strategic give attention to the Working Room to supply modern surgical options for our key clients.

“We’re pleased with the spectacular achievements our extremely expert staff have realized over the previous years and are grateful to have had the chance to guard and enhance the well being of sufferers in want of cartilage restore.  Shifting ahead, we’re happy that the product and manufacturing know-how is now bundled at Octane, forming the idea for much more patient-centric improvements. With this in thoughts, we imagine that our long-term companion Octane and its staff have a robust potential to additional scale the enterprise and make NOVOCART merchandise obtainable to much more sufferers.”

Article content material

“With over 120,000 sq. ft (11,000 sq. meters) throughout three websites positioned in Canada, U.S.A. and Germany, Octane will be capable of leverage shared efficiencies for product growth, GMP (good manufacturing apply) manufacturing, regulatory submissions and medical rollout,” stated Smith. “We’re properly positioned, because of our multidisciplinary crew, to commercialize our portfolio in a number of key market sectors. Driving ahead, Octane will proceed to give attention to stellar expertise, distinctive science and game-changing merchandise.”

ABOUT OCTANE MEDICAL GROUP
Headquartered in Ontario, Canada with areas in america and Europe, Octane is a worldwide group of firms with probably the most superior bioprocesses, biomaterials and bioreactors for regenerative drugs. We energy transformative healthcare with game-changing applied sciences that we develop and switch into proof-of-concept platforms. These improvements are superior into manufacturing inside our market-specific Octane ventures after which launched for commercialization with our world companions. At this time, our Octane ventures embrace Octane Medical Techniques, Octane Orthobiologics, Octane Exo, Octane Biotech and Octane Biotherapeutics (BioTx).

Article content material

At Octane, our objective is to make regenerative drugs the usual of care. For extra data, go to www.octaneco.com.

ABOUT B. Braun
B. Braun is likely one of the world’s main medical expertise firms. With 63,000 staff, B. Braun is a real companion growing good options and setting requirements to drive developments in well being care. In 2023, the B. Braun Group recorded 8.8 billion euros in gross sales. For extra data go to www.bbraun.com    

Article content material